We subsequently developed a protocol for combined Cas9-based gene disruption and lentiviral transduction to generate gene modified human CAR T cells, and then tested whether Cas9-mediated disruption of PD-1 in CAR T cells improved anti-tumor efficacy in vitro and in vivo using a xenograft tumor model. Here, PDCD1 is linked to neoplasm.